Results 201 to 210 of about 272,037 (262)

HER2/neu Expression in Low-Grade Serous Ovarian Carcinoma: A Pilot Two-Center Retrospective Study. [PDF]

J Clin Med
Badlaeva A, Asaturova A, Rogozhina A, Ezhova L, Arzhanukhina N, Tregubova A, Rogozhin D, Sukhikh G.   +7 more
europepmc   +1 more source

DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K/Akt/GSK‐3β/β‐Catenin Signaling Pathway in Breast Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Aspartyl‐tRNA synthetase 2 (DARS2), the mitochondrial enzyme responsible for aminoacylation of aspartyl‐tRNA, is traditionally known for its effect on protein synthesis. Recently, DARS2 is reported to be implicated in tumorigenesis. However, its specific effect on breast cancer (BC) is poorly understood.
Na Wang, Ming Huang
wiley   +1 more source

NKG2A inhibition promotes NK cell-CD8⁺ T cell interactions to improve anticancer immunity in ovarian carcinoma. [PDF]

Nat Commun
Lanickova T, Angelidou A, Hensler M, Vankerckhoven A, Niederlova V, Vosahlikova S, Kasikova L, Bock A, Zacharova E, Stekas C, Tunkova B, Tomankova J, Glatzova D, Moserova I, Drozenova J, Cveckova B, Shankar T, Laco J, Ryska A, Dundr P, Ndukwe MI, Cibula D, Vachtenheim J, Lischke R, Capkova L, Kovar M, Halaska MJ, Rob L, Allonsius L, Laoui D, Hanns A, Cremer I, Orsulic S, Stepanek O, Jacob F, Galluzzi L, Spisek R, Fucikova J.   +37 more
europepmc   +1 more source

Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies. [PDF]

Gynecol Oncol Rep
Jang M, Gysler S, Latif NA, Ko EM, Giuntoli RL, Kim SH, Simpkins F, Nasioudis D.   +7 more
europepmc   +1 more source

Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist's perspective. [PDF]

J Ovarian Res
Alves-Vale C, Galvão B, Silvestre AR, Pereira JS, Bei L, Fernandes JP, Borralho P, Carmo-Fonseca M, Custódio N.   +8 more
europepmc   +1 more source

Construction of nomograms for predicting overall survival and progression-free survival in patients with high-grade serous ovarian carcinoma: a retrospective study. [PDF]

PeerJ
Shan Y, Song K, Shan Z, Han F, Li L, Chu H.   +5 more
europepmc   +1 more source

Unveiling the Diagnostic Significance of Calprotectin in Serous Ovarian Carcinoma. [PDF]

Life (Basel)
Matsas A, Stamoula E, Kontzoglou K, Eleftheriades M, Tsokkou S, Christopoulos P, Panoskaltsis T, Polydorou E, Sotiropoulos I, Troupis T, Iliopoulos DC.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mucinous Ovarian Carcinoma

New England Journal of Medicine, 2019
(Abstracted from N Engl J Med 2019;380:1256–1266) Mucinous ovarian cancer is a rare form of epithelial ovarian cancer, accounting for approximately 3% of all cases. New understanding of the biological features of this unique disease requires an update to traditional diagnostic and therapeutic protocols that have been historically based on ...
Morice, Philippe, Gouy, Sebastien, Leary, Alexandra   +2 more
openaire   +5 more sources